Kanjinti
Kanjinti Uses, Dosage, Side Effects, Mechanism of Action, How Long Does it Take to Work? Kanjinti is a brand name. Its generic name is Trastuzumab.
What is Kanjinti?
Kanjinti is a type of monoclonal antibody used to treat certain types of breast cancer. It is a tumor suppressor, meaning it helps to slow the growth and spread of tumor cells.
Uses of Kanjinti
Kanjinti is primarily used to treat HER2-positive metastatic breast cancer and HER2-overexpressing early-stage breast cancer. Kanjinti is also indicated for the treatment of gastric cancer in combination with other medications. It may also be used in combination with other cancer treatments to reduce the risk of cancer recurrence.
Mechanism of Action
Kanjinti works by binding to HER2 receptors on cancer cells. This blocks the growth and spread of the cancer cells, thus suppressing the growth of the tumor and slowing the progression of the disease.
How Long Does It Take to Work?
The effects of trastuzumab can start to be seen within 2-4 weeks after beginning treatment. It is important to follow up regularly with your doctor to ensure that your cancer is responding to the treatment.
Absorption, Route of Elimination and Dosage
Kanjinti is administered intravenously. It is rapidly absorbed and its half-life is about 28 days. Dosing of trastuzumab varies and should be determined by a doctor. Usual dosing is 4mg/kg body weight for a single dose, followed by doses of 2mg/kg every three weeks until the desired response is achieved. Your doctor will usually start with a higher dose and then lower it if necessary.
Administration
Kanjinti is administered intravenously with an infusion pump. It is important that the solution is not heated and is well mixed prior to administration.
Side Effects
The most common side effects of trastuzumab include fatigue, nausea, vomiting, diarrhea, constipation, skin rash, and infusion site reactions. Other rare but serious side effects include heart problems, lung problems, and allergic reactions. Talk to your doctor before beginning treatment with trastuzumab.
Toxicity, Precaution and Interaction
Kanjinti has a low risk of toxicity. However, it is important to contact your doctor immediately if any signs of an allergic reaction are experienced, such as a rash, itching, or difficulty breathing. Kanjinti may also interact with other medications, so it is important to let your doctor know about any other medications you are taking.
Disease Interactions and Drug Interactions
Kanjinti can interact with some diseases, such as liver or kidney disease, and with some medications, such as aspirin, nonsteroidal anti-inflammatory drugs, and certain antibiotics. Talk to your doctor before beginning trastuzumab treatment if you have any concerns.
Food Interactions
Kanjinti may interact with some foods, such as caffeine, alcohol, and certain vitamins and minerals. It is important to discuss any dietary restrictions or concerns with your doctor before beginning treatment.
Pregnancy Use and Lactation Use
Kanjinti should not be used during pregnancy. Kanjinti is excreted in breast milk, so it should be avoided during lactation. Women should also not breastfeed while taking trastuzumab.
Acute Overdose
An overdose of trastuzumab can cause serious side effects, such as anaphylaxis and oliguria. If an overdose is suspected, contact your doctor immediately.
Contraindication
Kanjinti should not be used in people who are hypersensitive to it or any of its components. It is also contraindicated in people with prior exposure to any anti-HER2 therapies.
Use Direction, Storage Condition and Volume of Distribution
Kanjinti should only be used under the direction of a doctor. It should be stored at room temperature and must not be frozen or heated. The volume of distribution of trastuzumab is not known.
Half Life and Clearance
The half-life of trastuzumab is about 28 days and its clearance is not known.
Here you find in details version of Kanjinti
Some Frequently Asked Questions About Kanjinti
30 questions1. What is Kanjinti?
Kanjinti is a cancer treatment drug, an antibody used to treat certain types of advanced breast cancer. It is a recombinant DNA-derived humanized monoclonal antibody that binds to HER2 on cancer cells and halts their growth and spread.
2.How effective is Kanjinti?
Kanjinti has been found to be very effective in advanced breast cancer when used in combination with chemotherapy, and is estimated to improve overall response rate and progression-free survival by nearly 50%.
3. What type of cancer is treated with Kanjinti?
Kanjinti is used to treat breast cancer that is HER2-positive, meaning that it contains too many HER2 receptors that promote the growth and spread of the cancer cells.
4. How is Kanjinti administered?
Kanjinti is administered intravenously by a healthcare professional in a hospital or clinic.
5. How long does Kanjinti treatment last?
Kanjinti treatment can last anywhere from a few weeks to several months, depending on the severity of the cancer and how well the individual responds to the treatment.
6. What side effects does Kanjinti cause?
Kanjinti can cause a variety of side effects including fever, chills, fatigue, nausea and vomiting, headache, rash, joint pain, and low white blood cell count.
7. What is the cost of Kanjinti?
Kanjinti can cost anywhere from $35,000 to $50,000 per year.
8. Is Kanjinti safe to use?
Kanjinti has been found to be generally safe when administered correctly and monitored by a healthcare professional.
9. Is Kanjinti available worldwide?
Kanjinti is available in many countries around the world.
10. Is Kanjinti FDA approved?
Kanjinti is approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced breast cancer.
11. How often is Kanjinti given?
Kanjinti is typically given once every 3 weeks in combination with chemotherapy.
12. Who should not use Kanjinti?
Kanjinti is not recommended for those with an allergy to the drug or in individuals with healthy kidneys or liver, as it can cause kidney or liver damage. It should not be used in pregnant women, as it can cause harm to an unborn baby. Additionally, it is not recommended for individuals with a weakened immune system.
13. Is Kanjinti the same as Herceptin?
Yes, Kanjinti and Herceptin are the same drug.
14. Can Kanjinti cause hair loss?
Kanjinti can potentially cause hair loss as a side effect, but it is usually reversible.
15. Are there any clinical trials for Kanjinti?
Yes, currently there are over 100 clinical trials for Kanjinti.
16. How long does it take for Kanjinti to start working?
Kanjinti usually starts working within several weeks of administration, but it can take a few months for it to reach its peak effectiveness.
17. Is there an alternative to Kanjinti?
The alternative to Kanjinti is Lapatinib, which is a HER2 inhibitor drug.
18. Is Kanjinti safe for children?
Kanjinti is not recommended for use in children.
19. What type of cancer is Kanjinti used for?
Kanjinti is used to treat HER2-positive breast cancer.
20. Is Kanjinti a chemotherapy drug?
No, Kanjinti is an antibody drug used in combination with chemotherapy to treat breast cancer.
21. Does Kanjinti have any long-term effects?
Yes, there have been reports of long-term effects such as heart failure, osteoporosis, and increased risk of infection in those who have used Kanjinti.
22. Can Kanjinti cure cancer?
No, Kanjinti cannot cure cancer, but it can help reduce the amount of cancer cells in the body and help improve symptoms.
23. Is Kanjinti covered by insurance?
The coverage of Kanjinti depends on your insurance provider and policy.
24. How long does Kanjinti stay in the body?
Kanjinti is cleared from the body within a few days of administration.
25. Is Kanjinti given intravenously or orally?
Kanjinti is given intravenously.
26. Can Kanjinti be used with other cancer treatments?
Yes, Kanjinti can be used in combination with other cancer treatments, such as chemotherapy.
27. Is Kanjinti only used for breast cancer?
Yes, Kanjinti is only used to treat HER2-positive breast cancer.
28. Is Kanjinti used for early or late-stage breast cancer?
Kanjinti is typically used in late-stage breast cancer, when the cancer has spread beyond the breast.
29. Are there any gender restrictions for taking Kanjinti?
No, Kanjinti can be used in both men and women.
30. Can Kanjinti be used in combination with other drugs?
Yes, Kanjinti can be used in combination with other drugs, such as chemotherapy.